Neutrophil elastase stimulates MUC1 gene expression through increased Sp1 binding to the MUC1 promoter.
We previously reported MUC1 was a cell surface receptor for Pseudomonas aeruginosa, and binding of bacteria to cells was significantly reduced by pretreatment with neutrophil elastase (NE) (Lillehoj EP, Hyun SW, Kim BT, Zhang XG, Lee DI, Rowland S, and Kim KC. Am J Physiol Lung Cell Mol Physiol 280: L181-L187, 2001). The current study was conducted to ascertain NE effects on MUC1 gene transcription, and MUC1 protein synthesis and degradation. A549 human lung carcinoma cells treated with NE exhibited significantly higher MUC1 protein levels in detergent lysates compared with cells treated with vehicle alone. Also, MUC1 protein shed into cell-conditioned medium was rapidly and completely degraded by NE. Actinomycin D blocked NE-stimulated increase in MUC1 protein expression, suggesting a mechanism of increased gene transcription that was confirmed by measurement of quantitatively greater MUC1 mRNA levels in NE-treated cells compared with controls. However, NE did not alter MUC1 mRNA stability, implying increased de novo transcription induced by the protease. NE increased promoter activity in A549 cells transfected with MUC1 gene promoter-luciferase reporter plasmid. This effect of NE was completely blocked by mithramycin A, an inhibitor of Sp1, as well as mutation of one of the putative Sp1 binding sites in MUC1 promoter located at -99/-90 relative to transcription initiation site. EMSA revealed NE enhanced binding of Sp1 to this 10-bp segment in a time-dependent manner. These results indicate the increase in MUC1 gene transcription by NE is mediated through increase in Sp1 binding to -99/-90 segment of MUC1 promoter.
Kuwahara
Ippei
I
Dept. of Pharmaceutical Sciences, School of Pharmacy, Univ. of Maryland, 20 Penn St., Baltimore, MD 21201, USA.
Lillehoj
Erik P
EP
Hisatsune
Akinori
A
Lu
Wenju
W
Isohama
Yoichiro
Y
Miyata
Takeshi
T
Kim
K Chul
KC
D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism; D001665:Binding Sites; D003609:Dactinomycin / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D019272:Leukocyte Elastase / Q000378:metabolism*; D008156:Luciferases; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism; D018396:Mucin-1 / Q000235:genetics* / Q000378:metabolism; D008926:Plicamycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D020871:RNA Stability; D020218:Response Elements; D016329:Sp1 Transcription Factor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D024363:Transcription Initiation Site; D014158:Transcription, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured
D018396:Mucin-1; D011500:Protein Synthesis Inhibitors; D016329:Sp1 Transcription Factor; D003609:Dactinomycin; C066851:mithramycin A; D008156:Luciferases; D019272:Leukocyte Elastase; D008926:Plicamycin